

Datasheet: 5685-3557

| | |
|----------------------|---|
| Description: | NATIVE HUMAN LOW DENSITY LIPOPROTEIN (OXIDIZED) |
| Name: | LOW DENSITY LIPOPROTEIN (OXIDIZED) |
| Format: | Purified |
| Product Type: | Purified Protein |
| Quantity: | 2 mg |

Product Details

Applications

This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit www.bio-rad-antibodies.com/protocols.

| | Yes | No | Not Determined | Suggested Dilution |
|-------------------|-----|----|----------------|--------------------|
| Functional Assays | ▪ | | | |

Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using the appropriate negative/positive controls.

| | |
|---------------------------------------|---|
| Target Species | Human |
| Product Form | Purified oxidised LDL from human plasma - liquid |
| Preparation | LDL is purified to homogeneity by ultra-centrifugation. Oxidised using 20 µM cupric sulphate in PBS at 37°C for 24 hours. Oxidation is terminated with excess EDTA. The level of oxidation is measured using TBARS (Thiobarbituric acid reactive substances) determination using a Malondialdehyde (MDA) standard. The level of oxidation is batch specific and available on request. |
| Buffer Solution | Phosphate buffered saline |
| Preservative Stabilisers | 0.3 mM EDTA |
| Approx. Protein Concentrations | Total protein concentration 2.0 mg/ml |

Product Information **Native oxidized Human Low Density Lipoprotein** is provided, purified from human plasma in liquid form. (LDL) oxidative modification is one of the major processes involved in atherosclerosis along with other degenerative disorders. Oxidized LDL is preferentially accumulated by macrophages which become so called "foam cells" within the atheromatous plaque and contributes to the accumulation of cholesterol, typical of atherosclerosis.

References

1. Yang, K. *et al.* (2015) Oxidized low-density lipoprotein promotes macrophage lipid accumulation via the toll-like receptor 4-*Src* pathway. [Circ J. 79 \(11\): 2509-16.](#)
2. Wang, X. Q. *et al.* (2016) C1q/TNF-related protein 1 links macrophage lipid metabolism to inflammation and atherosclerosis [Atherosclerosis. Apr 28 \[Epub ahead of print\]](#)

3. Dai, D. *et al.* (2016) Association of decreased serum sTREM-1 level with the severity of coronary artery disease: Inhibitory effect of sTREM-1 on TNF- α - and oxLDL-induced inflammatory reactions in endothelial cells. [Medicine \(Baltimore\). 95 \(37\): e4693.](#)
4. Zhang, B-C. *et al.* (2016) Luteolin Attenuates Foam Cell Formation and Apoptosis in Ox-LDL-Stimulated Macrophages by Enhancing Autophagy. [Cell Physiol Biochem. 39 \(5\): 2065-2076.](#)
5. Fukushi, S. *et al.* (2018) Characterization of novel monoclonal antibodies against the MERS-coronavirus spike protein and their application in species-independent antibody detection by competitive ELISA. [J Virol Methods. 251: 22-29.](#)
6. Carbone, M.L. *et al.* (2017) Leukocyte RhoA exchange factor Arhgef1 mediates vascular inflammation and atherosclerosis. [J Clin Invest. Nov 13 \[Epub ahead of print\].](#)

Storage This product is stable for approximately 4 weeks when handled aseptically and stored at +4°C. DO NOT FREEZE. This product should be stored undiluted.

Guarantee Guaranteed until date of expiry. Please see product label.

Health And Safety Information Material Safety Datasheet documentation #10136 available at: 10136: <https://www.bio-rad-antibodies.com/uploads/MSDS/10136.pdf>

Donor material tested and found negative for HIV1, HIV2, HIV1 antigen, HBsAg, the antibody to HTLV1, HCV, HBcAg, ALT and syphilis.

As no test can completely guarantee this material to be free of pathogens it should be handled as potentially infectious.

Regulatory For research purposes only

| | | | | | |
|----------------------------------|---|------------------|---|---------------|---|
| North & South America | Tel: +1 800 265 7376 Fax: +1 919 878 3751 Email: antibody_sales_us@bio-rad.com | Worldwide | Tel: +44 (0)1865 852 700 Fax: +44 (0)1865 852 739 Email: antibody_sales_uk@bio-rad.com | Europe | Tel: +49 (0) 89 8090 95 21 Fax: +49 (0) 89 8090 95 50 Email: antibody_sales_de@bio-rad.com |
|----------------------------------|---|------------------|---|---------------|---|

'M350207:190307'

Printed on 20 May 2019

© 2019 Bio-Rad Laboratories Inc | [Legal](#) | [Imprint](#)